Advertisement

Prediction of acute coronary syndrome, ischemic stroke, and mortality in patients with heart failure: a comparison of CHA2DS2-VASc and AHEAD scores

  • Wei-Syun HuEmail author
  • Cheng-Li Lin
Article

Abstract

Purpose

To compare the predictive capacity of the CHA2DS2-VASc and AHEAD scores in predicting acute coronary syndrome (ACS), ischemic stroke (IS), and mortality in patients with heart failure (HF).

Methods

A total of 404,635 patients hospitalized for HF between 2000 and 2011 were recruited from a large national database in Taiwan. The predictive value of both scores was evaluated by analysis of the area under the receiver operating characteristic curve (AUROC), and the difference in their discriminative capacity was assessed using the DeLong test.

Results

The AUROC for the CHA2DS2-VASc score was significantly higher than that for the AHEAD score in predicting ACS and IS: 0.53 (95% CI = 0.53–0.54) versus 0.51 (95% CI = 0.51–0.52) for ACS, and 0.57 (95% CI = 0.56–0.57) versus 0.52 (95% CI = 0.51–0.52) for IS, respectively (all DeLong tests p < 0.001). By contrast, for mortality risk, the AUROC was significantly lower for the CHA2DS2-VASc score (0.56, 95% CI = 0.55–0.56) than the AHEAD score (0.60, 95% CI = 0.59–0.60; DeLong test p < 0.001).

Conclusions

The ability of the CHA2DS2-VASc score to predict macrovascular complications (ACS and IS) in HF patients was higher than that of AHEAD.

Keywords

Acute coronary syndrome AHEAD score CHA2DS2-VASc score Heart failure Ischemic stroke Mortality 

Notes

Acknowledgements

This study was supported in part by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW106-TDU-B-212-113004).

References

  1. 1.
    Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93:1137–46.CrossRefGoogle Scholar
  2. 2.
    Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–e220.Google Scholar
  3. 3.
    Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J. 2013;77(9):2209–17.CrossRefGoogle Scholar
  4. 4.
    Spinar J, Jarkovsky J, Spinarova L, Mebazaa A, Gayat E, Vitovec J, et al. AHEAD score--long-term risk classification in acute heart failure. Int J Cardiol. 2016;202:21–6.CrossRefGoogle Scholar
  5. 5.
    Chen YJ, Sung SH, Cheng HM, Huang WM, Wu CL, Huang CJ, Hsu PF, Yeh JS, Guo CY, Yu WC, Chen CH. Performance of AHEAD score in an Asian cohort of acute heart failure with either preserved or reduced left ventricular systolic function. J Am Heart Assoc. 2017;6(5).Google Scholar
  6. 6.
    Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57(11):e101–98.CrossRefGoogle Scholar
  7. 7.
    Cetin M, Cakici M, Zencir C, Tasolar H, Baysal E, Balli M, et al. Prediction of coronary artery disease severity using CHADS2 and CHA2DS2-VASc scores and a newly defined CHA2DS2-VASc-HS score. Am J Cardiol. 2014;113(6):950–6.CrossRefGoogle Scholar
  8. 8.
    Paoletti Perini A, Bartolini S, Pieragnoli P, Ricciardi G, Perrotta L, Valleggi A, et al. CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy. Europace. 2014;16(1):71–80.CrossRefGoogle Scholar
  9. 9.
    Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA. 2015;314(10):1030–8.CrossRefGoogle Scholar
  10. 10.
    Ye S, Qian M, Zhao B, Buchsbaum R, Sacco RL, Levin B, et al. CHA2DS2 -VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. Eur J Heart Fail. 2016;18:1261–6.CrossRefGoogle Scholar
  11. 11.
  12. 12.
    Hu WS, Sung FC, Lin CL. Aplastic anemia and risk of incident atrial fibrillation—a nationwide cohort study. Circ J. 2018;82(5):1279–85.CrossRefGoogle Scholar
  13. 13.
    Harnod T, Lin CL, Kao CH. Risk of suicide attempt in poststroke patients: a population-based cohort study. J Am Heart Assoc J Am Heart Assoc. 2018;7(2).Google Scholar
  14. 14.
    Hu WS, Lin CL. Comparison of CHA2DS2-VASc, CHADS2 and HATCH scores for the prediction of new-onset atrial fibrillation in cancer patients: a nationwide cohort study of 760,339 study participants with competing risk analysis. Atherosclerosis. 2017;266:205–11.CrossRefGoogle Scholar
  15. 15.
    Hu WS, Lin CL. The predictive role of CHA2DS2-VASc score between venous thromboembolism and ischemic stroke: a large-scale cohort study. J Hypertens. 2018;36(3):628–33.CrossRefGoogle Scholar
  16. 16.
    January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–76.CrossRefGoogle Scholar
  17. 17.
    Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–47.CrossRefGoogle Scholar
  18. 18.
    Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263–72.CrossRefGoogle Scholar
  19. 19.
    Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence—what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–7.CrossRefGoogle Scholar
  20. 20.
    de Lusignan S, Crawford L, Munro N. Creating and using real-world evidence to answer questions about clinical effectiveness. J Innov Health Inform. 2015;22(3):368–73.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.School of Medicine, College of MedicineChina Medical UniversityTaichungTaiwan
  2. 2.Division of Cardiovascular Medicine, Department of MedicineChina Medical University HospitalTaichungTaiwan
  3. 3.Management Office for Health DataChina Medical University HospitalTaichungTaiwan

Personalised recommendations